Marc Schorpion - Argenx NV Global Resources
| ARGX Stock | USD 623.82 2.21 0.35% |
Executive
Marc Schorpion is Global Resources of argenx NV ADR
| Age | 65 |
| Address | Laarderhoogtweg 25, Amsterdam, Netherlands, 1101EB |
| Phone | 31 10 703 8441 |
| Web | https://www.argenx.com |
Argenx NV Management Efficiency
The company has return on total asset (ROA) of (0.0551) % which means that it has lost $0.0551 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0574) %, meaning that it created substantial loss on money invested by shareholders. Argenx NV's management efficiency ratios could be used to measure how well Argenx NV manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.07 in 2024. Return On Capital Employed is likely to drop to -0.11 in 2024. At this time, Argenx NV's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 439.7 M in 2024, whereas Other Current Assets are likely to drop slightly above 113.9 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Brian Austad | Karyopharm Therapeutics | N/A | |
| Robert Arbeit | X4 Pharmaceuticals | 76 | |
| Pharm MPH | X4 Pharmaceuticals | N/A | |
| Andrew Henry | Fate Therapeutics | 60 | |
| Jim MBA | Fate Therapeutics | N/A | |
| Barbra Sasu | Allogene Therapeutics | N/A | |
| David JD | Allogene Therapeutics | 53 | |
| Sonja MD | Sana Biotechnology | 49 | |
| Eric Schmidt | Allogene Therapeutics | 54 | |
| Snehal Patel | Sana Biotechnology | N/A | |
| Cindy Tahl | Fate Therapeutics | 51 | |
| Barbara Hickingbottom | Fate Therapeutics | N/A | |
| Katherine Bock | Arcus Biosciences | N/A | |
| Mark MBA | X4 Pharmaceuticals | 60 | |
| Timothy MBA | Caribou Biosciences | 55 | |
| Elhan CFA | Karyopharm Therapeutics | N/A | |
| Farah Anwar | Sana Biotechnology | N/A | |
| Bahram Valamehr | Fate Therapeutics | 47 | |
| Brett Fleshman | Heron Therapeuti | N/A | |
| Stuart Poulton | Karyopharm Therapeutics | N/A | |
| PharmD D | Heron Therapeuti | 62 | |
Management Performance
| Return On Equity | -0.0574 | ||||
| Return On Asset | -0.0551 |
argenx NV ADR Leadership Team
Elected by the shareholders, the Argenx NV's board of directors comprises two types of representatives: Argenx NV inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Argenx. The board's role is to monitor Argenx NV's management team and ensure that shareholders' interests are well served. Argenx NV's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Argenx NV's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Karen Massey, Chief Officer | ||
| Beth DelGiacco, VP Relations | ||
| EMBA MBA, CEO Director | ||
| Filip Borgions, VP Operations | ||
| Arjen MSc, Vice Strategy | ||
| Karl Gubitz, Chief Officer | ||
| Luc Truyen, Chief Officer | ||
| Malini Moorthy, General Counsel | ||
| MSc EMBA, CEO Director | ||
| Peter Ulrichts, Chief Officer | ||
| Pr Ir, CoFounder Officer | ||
| Keith Woods, Chief Officer | ||
| David MD, Advisor | ||
| Andria Wilk, Global Quality | ||
| Marc Schorpion, Global Resources |
Argenx Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Argenx NV a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0574 | ||||
| Return On Asset | -0.0551 | ||||
| Profit Margin | (0.02) % | ||||
| Operating Margin | 0.03 % | ||||
| Current Valuation | 34.57 B | ||||
| Shares Outstanding | 59.8 M | ||||
| Shares Owned By Institutions | 59.76 % | ||||
| Number Of Shares Shorted | 1.96 M | ||||
| Price To Earning | 5.54 X | ||||
| Price To Book | 8.78 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Argenx Stock Analysis
When running Argenx NV's price analysis, check to measure Argenx NV's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Argenx NV is operating at the current time. Most of Argenx NV's value examination focuses on studying past and present price action to predict the probability of Argenx NV's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Argenx NV's price. Additionally, you may evaluate how the addition of Argenx NV to your portfolios can decrease your overall portfolio volatility.